4
Changes in Ownership
SAB Biotherapeutics, Inc. Filed Acc 0001493152-21-028917
Chief Financial Officer sold 278 shares at $7.90 ($2,196)
- Chief Financial Officer acquired 2,768 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Beyer Russell P · Chief Financial Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-10-18 | Grant or award : show line 1 in the form | +2,475 | $10.10 | $24,998 | 2,475 | D |
| 2021-09-28 | Grant or award : show line 2 in the form | +149 | $10.08 | $1,502 | 149 | I |
| 2021-10-25 | Grant or award : show line 3 in the form | +129 | $7.78 | $1,004 | 278 | I |
| 2021-10-26 | Sale : show line 4 in the form | −278 | $7.90 | $2,196 | 0 | I |
| 2021-09-28 | Grant or award : show line 5 in the form | +5 | $10.07 | $50 | 5 | I |
| 2021-09-29 | Grant or award : show line 6 in the form | +10 | $10.08 | $101 | 15 | I |
| Open-market sales · 278 sh · avg $7.90 · $2,196 | ||||||
Loading xslF345X03/ownership.xml…